Germany Pharmaceuticals & Healthcare Report Q4 2014 - New Market Report
Germany's medicine pricing regime will continue to restrict drugmakers' revenue streams. T he price freezes, cuts and discounts implemented in Germany are having a contagious effect, putting further pressure on drugmakers looking to benefit from marketing their products in other European markets. Despite this situation, Germany will remain an attractive market to drugmakers. The long-term and clear nature of the price measures implemented by the government can be viewed as a restructuring of the country's medicine pricing methodologies in comparison...
View full press release